Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,753 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04643041 | Watch and Wait in PD-1 Monoclonal Antibody Treated dMMR/MSI-H Distal Rectal Cancer(BASKET) | recruiting | N/A | 47 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT05953662 | Safety and Efficacy of Reduced-port Laparoscopic Surgery for Patients Of Colon and Upper Rectal Cancer | active not recruiting | N/A | 500 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 |
| Apr 27, 2026 |
| clinicaltrials |
| NCT06002789 | Safety and Efficacy of PD-1 ± mFOLFOX6 Neoadjuvant Therapy in Local Advanced sMPCC | recruiting | Phase 2 | 17 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT02633202 | Concurrent Chemotherapy for the Intermediate Risk Nasopharyngeal Carcinoma In Intensity-modulated Radiotherapy Era | completed | Phase 3 | 338 | Sun Yat-sen UniversityOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07297004 | Stereotactic Body Radiation Therapy for Unresectable Locally Recurrent Rectal Cancer | recruiting | Phase 2 | 20 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07392320 | A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal Carcinoma | recruiting | Phase 2 | 142 | Sun Yat-sen UniversityOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07549906 | Neoadjuvant Iparomlimab/Tuvonralimab Plus CAPEOX Versus Iparomlimab/Tuvonralimab Plus CAPEOX and Propranolol for Locally Advanced pMMR Colon Cancer: A Prospective, Single-Center, Multi-Cohort Study | not yet recruiting | Phase 2 | 45 | Sun Yat-sen UniversityOTHER | 0 | Apr 24, 2026 | clinicaltrials |
| NCT07550855 | Sonrotoclax, Zanubrutinib and Rituximab in Previously Untreated Patients With Follicular Lymphoma(FLOURISH) | not yet recruiting | Phase 2 | 52 | Sun Yat-sen UniversityOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT03810339 | Toripalimab(JS001) as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors | recruiting | Phase 2 | 35 | Sun Yat-sen UniversityOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT04989621 | Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL) | recruiting | Phase 2 | 32 | Sun Yat-sen UniversityOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT05523245 | Predicting the Efficacy of Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer Using an AI Platform Based on Multi-parametric MRI(DLARC) | recruiting | — | 1,700 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06140992 | PaCIFiC-CUP Classifies Cancer of Unknown Primary | recruiting | — | 120 | Sun Yat-sen UniversityOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06143748 | Combination of Cadonilimab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-006)(EC-CRT-006) | active not recruiting | Phase 2 | 46 | Sun Yat-sen UniversityOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06426511 | ctDNA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLC(CONTINUE) | recruiting | Phase 2 | 80 | Sun Yat-sen UniversityOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06767007 | SBRT + PD-1 Antibody in Unresectable Locally Recurrent Rectal Cancer(SPARKLE) | recruiting | Phase 2 | 31 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06889688 | Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer | recruiting | Phase 3 | 246 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT07548736 | Improvement Effect of Dexamethasone Enema for Acute Radiation-induced Rectal Injury | not yet recruiting | Phase 2 | 40 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT07548762 | Endoscopic Skin-Sparing vs. Conventional Mastectomy for Wound Complications in BC | recruiting | N/A | 258 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT07353294 | Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UC | enrolling by invitation | Phase 1 | 12 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT07540390 | GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC. | not yet recruiting | Phase 3 | 442 | Sun Yat-sen UniversityOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT07543510 | Low-Dose Bevacizumab and Atezolizumab Combined With TACE-HAIC in Unresectable Hepatocellular Carcinoma | not yet recruiting | N/A | 38 | Third Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 0 | Apr 22, 2026 | clinicaltrials |
| NCT03872661 | Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC(NIBCUN) | recruiting | Phase 2 | 36 | Sun Yat-sen UniversityOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT06138496 | Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC | completed | Phase 2 | 39 | Sun Yat-sen UniversityOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT06563999 | Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.(NUMER) | recruiting | Phase 2 | 120 | Sun Yat-sen UniversityOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT07177794 | Consolidation of Toripalimab and Capecitabine After Chemoradiotherapy in ESCC(EC-CRT-008) | recruiting | Phase 3 | 242 | Sun Yat-sen UniversityOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT07378306 | FMD and Neoadjuvant Chemo-immunotherapy in TNBC(FACT-TN) | recruiting | Phase 2 | 80 | Sun Yat-sen UniversityOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT07542912 | Sintilimab, Chidamide, and Azacitidine for Untreated Stage I-II Extranodal NK/T-Cell Lymphoma(SCENT-3) | not yet recruiting | N/A | 30 | Sun Yat-sen UniversityOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT06190301 | RCT on Intralesional Rituximab Injection Versus ISRT in Ocular Adnexal MALT Lymphoma | recruiting | N/A | 108 | Zhongshan Ophthalmic Center, Sun Yat-sen UniversityOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT06280495 | Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients | recruiting | Phase 2 / Phase 3 | 156 | Sun Yat-sen UniversityOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07538180 | Serplulimab, Chidamide, and Rituximab Followed by Sequential R-CHOP for Newly Diagnosed Elderly MYC/BCL2 Double-Expressor DLBCL(SCREEN) | active not recruiting | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07540377 | Real-World Study on Efficacy and Influencing Factors of Immunotherapy for Pan-Cancer Lymph Node Metastases. | not yet recruiting | — | 5,000 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07537985 | Efficacy and Safety Comparison Between PD-1 Inhibitor Combined With Lenvatinib or With Regorafenib For UHCC After Failure of First-line Treatment | completed | N/A | 200 | Sun Yat-sen UniversityOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT05493020 | The Association Between Watching Mukbang Videos and the Appetite of Children With Cancer | completed | — | 179 | Sun Yat-sen UniversityOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT07533526 | Effects of Instrument-Assisted Constant-Speed Injection Versus Manual Injection on Pain From Large-Volume Subcutaneous Injection of Pertuzumab and Trastuzumab in Breast Cancer: A Randomized, Self-Controlled Study | not yet recruiting | N/A | 40 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT07530445 | Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer | recruiting | Phase 2 | 40 | Sun Yat-sen UniversityOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06583083 | Sintilimab With P-GEMOX Versus the P-GEMOX in the Teatment of Advanced-stage Extranodal Natural Killer/T Cell Lymphoma(SPIRIT-02) | recruiting | Phase 2 | 84 | Sun Yat-sen UniversityOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT07496190 | Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy | recruiting | Phase 2 | 59 | Sun Yat-sen UniversityOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07524413 | Becotatug Vedotin (MRG003) With PD-1 Blockade and Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma | not yet recruiting | Phase 3 | 514 | Sun Yat-sen UniversityOTHER | 0 | Apr 13, 2026 | clinicaltrials |
| NCT07520760 | A Multicenter, Single-Arm, Phase II Exploratory Study of Eribulin in Combination With Anlotinib for HER2-Negative Recurrent/Metastatic Breast Cancer Previously Treated With Antibody-Drug Conjugates(MBC-EA) | recruiting | Phase 2 | 52 | Sun Yat-sen UniversityOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT07516678 | Serial ctDNA and Molecular Residual Disease Monitoring in Neuroblastoma | recruiting | — | 200 | Sun Yat-sen UniversityOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT07518602 | Efficacy and Safety of Chidamide+Sintilimab+Bev as Second-Line Therapy in Advanced Extrapulmonary Neuroendocrine Carcinoma | recruiting | Phase 2 | 34 | Sun Yat-sen UniversityOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT07515430 | The Association Between Gut Microbiome Composition Signature and Cancer-related Symptoms in Children With Acute Lymphoblastic Leukemia | enrolling by invitation | — | 138 | Sun Yat-sen UniversityOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT06545747 | Adaptive Hypofractionated Radiotherapy for Locally Advanced NSCLC Based on Dynamic Enhanced MRI | recruiting | Phase 3 | 490 | Sun Yat-sen UniversityOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07481786 | Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases | recruiting | Phase 3 | 220 | Sun Yat-sen UniversityOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07512232 | Intraoperative Rectal Lavage to Prevent Local Recurrence After Laparoscopic Mid-to-Low Rectal Cancer Resection: A Multicenter Randomized Trial(TOWER-2) | recruiting | N/A | 1,598 | Sun Yat-sen UniversityOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07507526 | A Study of Disitamab Vedotin, Tunlametinib, and PD-1 Antibody for Advanced Gastric Cancer(DTP-HER2) | not yet recruiting | Phase 2 | 76 | Sun Yat-sen UniversityOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT06768931 | Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer | recruiting | Phase 2 | 192 | Sun Yat-sen UniversityOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07488325 | Multimodal Assessment of Malignancy in Atypia of Undetermined Significance in Thyroid Nodules Using Ultrasound and Cytology Whole-Slide Images | recruiting | — | 396 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07504367 | Large Language Models Assist in Tumor MDT | recruiting | N/A | 60 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT07501351 | Efficacy and Safety Comparison Between Intensified Therapy and Conversion Therapy For Advanced HCC After Failure of First-line | recruiting | Phase 2 | 80 | Sun Yat-sen UniversityOTHER | 1 | Mar 30, 2026 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials